OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
A Study to Evaluate Doravirine Pharmacokinetics When Coadministered With Acid‐Reducing Agents
Sauzanne Khalilieh, Ka Lai Yee, Rosa I. Sánchez, et al.
The Journal of Clinical Pharmacology (2019) Vol. 59, Iss. 8, pp. 1093-1098
Closed Access | Times Cited: 10
Sauzanne Khalilieh, Ka Lai Yee, Rosa I. Sánchez, et al.
The Journal of Clinical Pharmacology (2019) Vol. 59, Iss. 8, pp. 1093-1098
Closed Access | Times Cited: 10
Showing 10 citing articles:
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
Margaret Johnson, Princy Kumar, Jean‐Michel Molina, et al.
JAIDS Journal of Acquired Immune Deficiency Syndromes (2019) Vol. 81, Iss. 4, pp. 463-472
Open Access | Times Cited: 75
Margaret Johnson, Princy Kumar, Jean‐Michel Molina, et al.
JAIDS Journal of Acquired Immune Deficiency Syndromes (2019) Vol. 81, Iss. 4, pp. 463-472
Open Access | Times Cited: 75
Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial
Princy Kumar, Margaret Johnson, Jean‐Michel Molina, et al.
JAIDS Journal of Acquired Immune Deficiency Syndromes (2021) Vol. 87, Iss. 2, pp. 801-805
Open Access | Times Cited: 38
Princy Kumar, Margaret Johnson, Jean‐Michel Molina, et al.
JAIDS Journal of Acquired Immune Deficiency Syndromes (2021) Vol. 87, Iss. 2, pp. 801-805
Open Access | Times Cited: 38
Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine
Alison Boyle, Catherine E. Moss, Catia Marzolini, et al.
Clinical Pharmacokinetics (2019) Vol. 58, Iss. 12, pp. 1553-1565
Closed Access | Times Cited: 37
Alison Boyle, Catherine E. Moss, Catia Marzolini, et al.
Clinical Pharmacokinetics (2019) Vol. 58, Iss. 12, pp. 1553-1565
Closed Access | Times Cited: 37
An update on drug–drug interactions associated with proton pump inhibitors
Inès Ben Ghezala, Maxime Luu, Marc Bardou
Expert Opinion on Drug Metabolism & Toxicology (2022) Vol. 18, Iss. 5, pp. 337-346
Closed Access | Times Cited: 22
Inès Ben Ghezala, Maxime Luu, Marc Bardou
Expert Opinion on Drug Metabolism & Toxicology (2022) Vol. 18, Iss. 5, pp. 337-346
Closed Access | Times Cited: 22
Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug–Drug Interactions
Sauzanne Khalilieh, Ka Lai Yee, Rosa I. Sánchez, et al.
Clinical Drug Investigation (2020) Vol. 40, Iss. 10, pp. 927-946
Open Access | Times Cited: 22
Sauzanne Khalilieh, Ka Lai Yee, Rosa I. Sánchez, et al.
Clinical Drug Investigation (2020) Vol. 40, Iss. 10, pp. 927-946
Open Access | Times Cited: 22
Doravirine dose Selection and 96-Week Safety and Efficacy versus Efavirenz in Antiretroviral Therapy-Naive Adults with HIV-1 Infection in a Phase IIb Trial
José M. Gatell, Javier O Morales-Ramirez, Debbie Hagins, et al.
Antiviral Therapy (2018) Vol. 24, Iss. 6, pp. 425-435
Closed Access | Times Cited: 22
José M. Gatell, Javier O Morales-Ramirez, Debbie Hagins, et al.
Antiviral Therapy (2018) Vol. 24, Iss. 6, pp. 425-435
Closed Access | Times Cited: 22
Doravirine: A Return of the NNRTI Class?
Sarah Blevins, E. Kelly Hester, Daniel B. Chastain, et al.
Annals of Pharmacotherapy (2019) Vol. 54, Iss. 1, pp. 64-74
Closed Access | Times Cited: 12
Sarah Blevins, E. Kelly Hester, Daniel B. Chastain, et al.
Annals of Pharmacotherapy (2019) Vol. 54, Iss. 1, pp. 64-74
Closed Access | Times Cited: 12
Pharmacokinetics, safety and tolerability of long‐acting parenteral intramuscular injection formulations of doravirine
Ka Lai Yee, Sachin Mittal, Fan Li, et al.
Journal of Clinical Pharmacy and Therapeutics (2020) Vol. 45, Iss. 5, pp. 1098-1105
Open Access | Times Cited: 8
Ka Lai Yee, Sachin Mittal, Fan Li, et al.
Journal of Clinical Pharmacy and Therapeutics (2020) Vol. 45, Iss. 5, pp. 1098-1105
Open Access | Times Cited: 8
Therapeutic drug monitoring of antiretroviral drugs for the management of human immunodeficiency infection
Patrick D. DeArmond, Dustin R. Bunch
Therapeutic Drug Monitoring (2024), pp. 241-264
Closed Access
Patrick D. DeArmond, Dustin R. Bunch
Therapeutic Drug Monitoring (2024), pp. 241-264
Closed Access
Efficacy, Safety, and Tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Results Through Week 96 from IMPAACT 2014
Supattra Rungmaitree, Linda Aurpibul, Brookie M. Best, et al.
Journal of the Pediatric Infectious Diseases Society (2023) Vol. 12, Iss. 12, pp. 602-609
Closed Access | Times Cited: 1
Supattra Rungmaitree, Linda Aurpibul, Brookie M. Best, et al.
Journal of the Pediatric Infectious Diseases Society (2023) Vol. 12, Iss. 12, pp. 602-609
Closed Access | Times Cited: 1
